Avidity Biosciences, Inc.
General ticker "RNA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.8B (TTM average)
Avidity Biosciences, Inc. follows the US Stock Market performance with the rate: 52.6%.
Estimated limits based on current volatility of 0.3%: low 71.43$, high 71.73$
Factors to consider:
- Total employees count: 391 (+54.5%) as of 2024
- Top business risk factors: Need for additional capital, Limited operating history, Clinical trial success, Regulatory and compliance, Market competition
- Current price 47.7% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [18.50$, 48.43$]
- 2025-12-31 to 2026-12-31 estimated range: [11.55$, 32.56$]
Financial Metrics affecting the RNA estimates:
- Negative: with PPE of -10.6 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -8.79 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: Investing cash flow per share per price, % of -24.96 <= -14.38
Short-term RNA quotes
Long-term RNA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $9.22MM | $9.56MM | $10.90MM |
| Operating Expenses | $188.14MM | $245.16MM | $389.83MM |
| Operating Income | $-178.91MM | $-235.60MM | $-378.94MM |
| Non-Operating Income | $4.92MM | $23.38MM | $56.63MM |
| R&D Expense | $150.40MM | $190.97MM | $303.59MM |
| Income(Loss) | $-174.00MM | $-212.22MM | $-322.30MM |
| Profit(Loss)* | $-174.00MM | $-212.22MM | $-322.30MM |
| Stockholders Equity | $578.08MM | $500.76MM | $1,424.96MM |
| Assets | $638.80MM | $628.55MM | $1,563.89MM |
| Operating Cash Flow | $-136.27MM | $-119.06MM | $-300.87MM |
| Capital expenditure | $2.82MM | $4.23MM | $7.07MM |
| Investing Cash Flow | $-189.96MM | $-130.07MM | $-854.20MM |
| Financing Cash Flow | $346.17MM | $93.86MM | $1,192.36MM |
| Earnings Per Share** | $-3.34 | $-2.91 | $-2.89 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.